Changes to list of SARS-CoV-2 variants of concern, variants of interest, and variants under monitoring

ECDC reviews the variants list at least weekly and if changes are indicated, these are detailed here. When not listed, it indicates that the weekly review did not result in any changes.

29 July 2021
- Added C.1.2 as a variant under monitoring

22 July 2021
- Changed classification of C.37 (Lambda) from VUM to VOI. Added references to pre-print publications for evidence of impact on immunity for C.37.
- Added a new category of variants (De-escalated variants)
- Changed classification of B.1.427/B.1.429 (Epsilon) from VOI to De-escalated variants
- Changed classification of B.1.616 from VOI to De-escalated variants

24 June 2021
- Added B.1.617.2+K417N as a variant under monitoring

18 June 2021
- Added WHO naming to C.37 (Lambda)
- Added references on vaccine escape for B.1.617.2 (Delta)

03 June 2021
- Changed classification of B.1.617.3 from VOI to the variant under monitoring (VUM) category
- P.1+P681H added to the variant under monitoring (VUM) category

24 May 2021
- Changed classification of B.1.617.2 from VOI to VOC
- Added reference to pre-print for evidence for immunity for B.1.617.2
- Added reference to UK technical briefing 12 to evidence for B.1.617.2

20 May 2021
- Mutations affecting the S1 part of the spike protein S1/S2 junction domain (residues 613-705) have been added to the mutations of interest lists for each variant. The mutations of interest now include changes to spike protein residues 319-541 and 613-705, and any additional unusual changes specific to the variant.
- Changed Transmission in EU/EEA for B.1.617.2 from Sporadic/Outbreak to Community.
- Added reference to Public Health England technical briefing 11 to the evidence for increased transmissibility for B.1.617.2.
- Added reference to pre-print publications for evidence of impact on immunity for B.1.617.1.
- Added B.1.1.519 (first detected in Mexico) and AV.1 (first detected in the UK) to the monitoring category.

11 May 2021
- Added references to Public Health England technical briefings 9-10 to the evidence for increased transmissibility for B.1.617.2.